Orthofix Medical (NASDAQ:OFIX) Receives Buy Rating from Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of Orthofix Medical (NASDAQ:OFIX) in a research note published on Wednesday,Benzinga reports. Roth Mkm currently has a $22.00 price target on the medical device company’s stock.

A number of other brokerages also recently issued reports on OFIX. StockNews.com upgraded Orthofix Medical from a “hold” rating to a “buy” rating in a research report on Tuesday. Canaccord Genuity Group initiated coverage on Orthofix Medical in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $24.00 price objective on the stock. Finally, Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and increased their price objective for the stock from $18.00 to $24.00 in a research report on Friday, November 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.33.

Orthofix Medical Trading Down 1.4 %

Shares of OFIX stock opened at $17.26 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. Orthofix Medical has a 52-week low of $12.08 and a 52-week high of $20.73. The company has a market capitalization of $659.57 million, a PE ratio of -5.51 and a beta of 1.10. The business’s fifty day moving average is $17.93 and its 200 day moving average is $17.35.

Insider Activity at Orthofix Medical

In related news, CFO Julie Andrews sold 4,655 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the transaction, the chief financial officer now owns 28,312 shares of the company’s stock, valued at $506,501.68. This represents a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Massimo Calafiore sold 9,203 shares of the firm’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $17.14, for a total value of $157,739.42. Following the transaction, the chief executive officer now directly owns 124,151 shares in the company, valued at $2,127,948.14. This trade represents a 6.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,442 shares of company stock valued at $436,883 over the last 90 days. 2.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Orthofix Medical by 14.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 71,371 shares of the medical device company’s stock valued at $1,246,000 after buying an additional 8,772 shares during the last quarter. Soleus Capital Management L.P. grew its stake in shares of Orthofix Medical by 13.1% during the fourth quarter. Soleus Capital Management L.P. now owns 686,374 shares of the medical device company’s stock valued at $11,984,000 after buying an additional 79,441 shares during the last quarter. State of Wyoming grew its stake in shares of Orthofix Medical by 206.8% during the fourth quarter. State of Wyoming now owns 9,432 shares of the medical device company’s stock valued at $165,000 after buying an additional 6,358 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Orthofix Medical by 14.8% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 97,461 shares of the medical device company’s stock valued at $1,702,000 after buying an additional 12,578 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Orthofix Medical by 4.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,348 shares of the medical device company’s stock valued at $338,000 after buying an additional 836 shares during the last quarter. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.